Last updated on October 2018

MRD-directed Therapy for Low-risk and Intermediate-risk AML.


Brief description of study

Acute myeloid leukemia(AML) patients with favorable and intermediate cytogenetics at diagnosis are generally excluded from first-line allo-SCT. However, these patients may eventually relapse in some cases. Our previous study found that stratification of treatment based on cytogenetics and therapeutic response could benefit low and intermediate AML. To further verify the results, we conducted a prospective multi-center study. The purpose of this study is to establish risk stratification based on cytogenetics and minimal-residual-disease (MRD) analysis to determine whether a MRD-directed therapy for low and intermediate AML patients has positive results in terms of overall survival.

Clinical Study Identifier: NCT02870777

Contact Investigators or Research Sites near you

Start Over

Qifa Liu

Nanfang Hospital, Southern Medical University
Guangzhou, China
  Connect »